Journal article
44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Authors
Rojas CI; Lugowska I; Juergens R; Sacher A; Weindler S; Sendur MAN; Dziadziuszko R; Pal A; Alvarez EC; Ahern ES
Journal
ESMO Open, Vol. 9, ,
Publisher
Elsevier
Publication Date
February 1, 2024
DOI
10.1016/j.esmoop.2024.102273
ISSN
2059-7029